The following is a summary of “Facts and Hopes in Immunotherapy of Endometrial Cancer” published in the November 2022 issue of Clinical Cancer by Marín-Jiménez et al.


Immunotherapy combined with checkpoint inhibitors has emerged as the treatment of choice for various malignancies, including endometrial carcinoma, and has become the standard treatment technique. This is not an isolated incident. Pembrolizumab or dostarlimab is a treatment option that has been authorized for the treatment of malignancies with mismatch repair deficiencies. 

Pembrolizumab is another option for treating cancerous tumors, particularly those with a high mutational burden. The combination drug pembrolizumab/lenvatinib was just given the green light for usage in all patients who suffer from endometrial cancer. Endometrial cancer is a complicated disease that can manifest itself in a wide variety of molecular subgroups and can have a range of outcomes depending on the patient. When it comes to antigenicity and immunogenicity, the distinctions between molecular subgroups should be considered absolutely essential for developing more individualized approaches to immunotherapy. 

In this review, their goal is to summarize and discuss the current evidence of immunotherapy for endometrial cancer, also known as Facts, as well as the future opportunities of immunotherapy for endometrial cancer, also known as Hopes. To be more specific, researchers will be focusing their efforts on the important molecular and tumor microenvironment characteristics of The Cancer Genome Atlas endometrial cancer subtypes.

Source; aacrjournals.org/clincancerres/article-abstract/28/22/4849/710470/Facts-and-Hopes-in-Immunotherapy-of-Endometrial?redirectedFrom=full text